Animal health company Zoetis (NYSE: ZTS) beat Wall Street’s revenue expectations in Q3 2026, but sales fell by 1.3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.27 billion, close to analysts’ estimates. Its non-GAAP profit of $1.75 per share was 15.8% above analysts’ consensus estimates.
Is now the time to buy ZTS? Find out in our full research report (it’s free for active Edge members).
Zoetis (ZTS) Q3 2026 highlights:
- Revenue $2.39 billion vs S&P analysts’ estimates of $2.33 billion (1.3% year-on-year decline, 2.6% beat)
- Adjusted EPS $1.75 vs S&P analysts’ estimates of $1.51 (15.8% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $9.27 billion at the midpoint from $9.22 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $6.30 at the midpoint, a 1.6% increase
- Operating margin 36.1%, down from 38.5% in the same quarter last year
- Market capitalization $33.93 billion
StockStory’s take
Zoetis reported a decline in revenue and operating margin during the latest quarter, driven by continued weakness in its companion animal segment and heightened competition in key product lines. Management attributed the softness to reduced veterinary clinic visits, persistent affordability concerns among pet owners, and changes in the pet ownership mix favoring less medicalized animals. CEO Kristin Peck highlighted that “the mix of pets is also changing,” referencing the ongoing impact of housing costs on pet adoption trends and veterinary service demand.
Looking forward, Zoetis’ updated guidance is anchored in cautious assumptions about the macroeconomic environment and persistent competitive dynamics. Management emphasized a disciplined approach to resource allocation while maintaining investment in its innovation pipeline, particularly for upcoming launches in dermatology and pain management. CFO Jay Saccaro stressed that the company “will not be assuming improvements in the macro environment or pet owner spending trends” for the next year, signaling a measured outlook on both revenue and margin recovery.
Key insights from management’s remarks
Management pointed to a combination of market-specific headwinds, aggressive promotional strategies, and new product launches as key factors shaping the quarter, with segment-level performance varying significantly across geographies and product lines.
- Dermatology franchise under pressure: The companion animal dermatology segment saw double-digit declines due to heightened competition and market share loss in the U.S. and Europe. Zoetis responded with targeted promotional investments that slowed share loss but compressed margins.
- Promotional strategies and share stabilization: Management leaned on gross-to-net promotional activities to defend share in core products like Apoquel and Simparica Trio, especially in the U.S. While these moves slowed share losses, they weighed on pricing and gross margin. Peck noted, “We have had to be a little more focused on some of these gross-to-net investments.”
- International and livestock resilience: While companion animal sales lagged domestically, livestock revenue grew mid-to-high single digits globally, buoyed by demand for protein and successful vaccine and genetics product lines. International markets also delivered growth in parasiticides and pain management, with new launches such as Lenivia and Portela gaining early traction.
- Diagnostics and innovation pipeline: The diagnostics segment delivered double-digit growth, supported by recent acquisitions (VitalRADS, VPG) and ongoing adoption of next-generation point-of-care platforms. Management emphasized continued investment in diagnostics and lifecycle product extensions, including upcoming launches like Cytopoint long-acting and Simparica Duo.
- Cost discipline and operating structure: The company maintained flat operating expenses by executing cost and productivity programs, including reductions in incentive compensation and professional services. Saccaro highlighted a focus on further cost savings while continuing to fund key R&D initiatives, particularly in chronic kidney disease, oncology, and obesity treatment areas.
Drivers of future performance
Zoetis’ outlook for the coming year is shaped by continued competitive pressures, macroeconomic uncertainty, and the timing of new product launches across its portfolio.
- Sustained margin headwinds: Management expects ongoing promotional investments and product mix shifts to continue pressuring gross margins, particularly in companion animal. However, cost-saving efforts in SG&A and manufacturing are expected to partially offset these effects as new savings programs roll out.
- Innovation-driven growth potential: The company anticipates that launches of Cytopoint long-acting and Simparica Duo, alongside expected U.S. approval of Lenivia, will gradually contribute to revenue starting next year, though material impact is expected later as adoption ramps up.
- Livestock and emerging markets stability: Zoetis sees livestock and emerging market growth as reliable contributors, noting strong protein demand and local market resilience. Disease outbreaks, weather fluctuations, and evolving trade policies are acknowledged as ongoing risks that could influence year-to-year results.
Catalysts in upcoming quarters
In the coming quarters, our analyst team will focus on (1) signs of stabilization or recovery in companion animal market share, especially within dermatology and pain management, (2) the trajectory of gross margin improvement as cost-saving initiatives and new product launches take effect, and (3) sustained growth in diagnostics and livestock segments. The timing and impact of new regulatory approvals for Cytopoint long-acting and Simparica Duo will also be important markers for future performance.
Zoetis currently trades at $80.88, down from $89.23 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Stocks that trumped tariffs
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
